Korea Investment CORP Has $51.79 Million Stock Holdings in DexCom, Inc. $DXCM

Korea Investment CORP increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 103.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 769,664 shares of the medical device company’s stock after buying an additional 390,501 shares during the period. Korea Investment CORP owned 0.20% of DexCom worth $51,791,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of DXCM. Andra AP fonden acquired a new stake in DexCom during the second quarter worth approximately $26,000. Twin Peaks Wealth Advisors LLC acquired a new position in shares of DexCom in the second quarter valued at approximately $26,000. SJS Investment Consulting Inc. grew its position in shares of DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new position in shares of DexCom during the third quarter worth approximately $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of DexCom during the second quarter worth approximately $45,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $68.10 on Monday. The firm’s 50 day simple moving average is $70.69 and its 200 day simple moving average is $68.75. The firm has a market capitalization of $26.21 billion, a price-to-earnings ratio of 32.43, a P/E/G ratio of 1.32 and a beta of 1.48. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the previous year, the business earned $0.45 earnings per share. The company’s revenue was up 13.1% on a year-over-year basis. As a group, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Citigroup restated a “buy” rating and issued a $77.00 price target (up from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Canaccord Genuity Group set a $95.00 target price on DexCom and gave the stock a “buy” rating in a report on Friday, February 13th. Leerink Partners reissued an “outperform” rating and issued a $92.00 target price on shares of DexCom in a research report on Tuesday, December 16th. Finally, Weiss Ratings upgraded shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $85.18.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.